Virax Biolabs Group Limited Ordinary Shares (VRAX) — Financial Flexibility Index

Latest as of September 2025: -4.34x

Virax Biolabs Group Limited Ordinary Shares (VRAX) has a Financial Flexibility Index of -4.34x as of September 2025. Free cash flow of $-2.78 Million (operating CF $-2.92 Million minus capex $141.50K) represents -4% of total liabilities ($641.52K). Check Virax Biolabs Group Limited Ordinary Sha (VRAX) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Financial Flexibility Index

-4.34x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-2.78 Million
Operating CF − Capex

Total Liabilities

$641.52K
USD

Capital Expenditures

$141.50K
USD

Virax Biolabs Group Limited Ordinary Shares Financial Flexibility Index (2020–2025)

Historical Financial Flexibility Index trend for Virax Biolabs Group Limited Ordinary Shares across 6 annual periods. For the full cash flow conversion analysis, see how efficiently does Virax Biolabs Group Limited Ordinary Sha generate cash.

Annual Financial Flexibility Index for Virax Biolabs Group Limited Ordinary Shares (2020–2025)

Year-by-year free cash flow to debt coverage for Virax Biolabs Group Limited Ordinary Shares. Explore cash flow to debt ratio of Virax Biolabs Group Limited Ordinary Sha to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -4.10x $-3.96 Million $-4.56 Million $964.75K ▲ +72.1%
2024 -14.72x $-5.08 Million $-6.25 Million $345.19K ▼ -234.3%
2023 -4.40x $-4.00 Million $-4.18 Million $908.40K ▼ -578.0%
2022 -0.65x $-809.07K $-809.07K $1.25 Million ▲ +4.1%
2021 -0.68x $-590.19K $-590.19K $871.43K ▼ -12.6%
2020 -0.60x $-744.61K $-744.61K $1.24 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities